Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) is a biotechnology company focused on noninvasive diagnostics and early detection of lung cancer and other lung diseases. News about bioAffinity Technologies often centers on its flagship product, CyPath® Lung, a noninvasive sputum-based test that uses advanced flow cytometry and proprietary artificial intelligence to identify cell populations indicating malignancy in high-risk patients.
Investors and clinicians following BIAF news will see updates on clinical performance and real-world use of CyPath® Lung, including case reports where the test has contributed to detecting Stage 1A lung cancer in patients with indeterminate pulmonary nodules and complex diagnostic profiles. Company announcements also describe growing test volumes, reported increases in CyPath® Lung revenues and adoption by physicians, health systems and Veterans Administration medical centers.
Another key news theme is regulatory and quality milestones. bioAffinity Technologies issues releases on the College of American Pathologists (CAP) accreditation status of its wholly owned subsidiary, Precision Pathology Laboratory Services, and on CLIA certification that underpins its laboratory operations. These updates highlight the laboratory’s role in delivering CyPath® Lung and other pathology services with an emphasis on quality, accuracy and patient safety.
News flow also covers intellectual property and platform development, including notifications of allowance for U.S. patents that protect the AI-built algorithm and flow cytometry platform behind CyPath® Lung, and accepted patent applications in jurisdictions such as Australia for systems and methods to determine lung health. In addition, bioAffinity Technologies reports on capital-raising activities, Nasdaq listing compliance, participation in scientific conferences like CHEST and the American Cancer Society National Lung Cancer Roundtable, and presentations that detail research on sample handling and diagnostic performance.
This BIAF news page aggregates these company disclosures, providing a single view of developments in noninvasive lung cancer diagnostics, laboratory quality achievements, patent progress and corporate actions related to bioAffinity Technologies.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced a conference call and audio webcast on November 14, 2022, at 8 a.m. ET to discuss its third-quarter 2022 financial and corporate results. The call is accessible via the company's Investor Relations website. bioAffinity is focused on noninvasive early-stage cancer diagnosis and targeted treatment, with its primary product, CyPath® Lung, demonstrating high sensitivity for early lung cancer detection. The company is involved in ongoing research at The University of Texas at San Antonio.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) recently announced the award of multiple patents in China, Mexico, and Australia for novel porphyrin conjugated compounds aimed at selective cancer treatment. These patents, valid until 2037, underscore the company's commitment to innovative cancer therapies, particularly as cancer rates rise in these regions. The company’s flagship product, CyPath® Lung, shows high sensitivity and specificity in early lung cancer detection, indicating strong potential for both diagnostic and therapeutic advancements in oncology.
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) is set to present its research on using flow cytometry for diagnosing lung diseases at the CHEST 2022 conference from Oct. 16-19, 2022. The presentation, led by PhD Lydia Bederka, will focus on Sputum Analysis By Flow Cytometry To Assess Lung Health on Oct. 19, highlighting the development of its product, CyPath® Lung, which detects early-stage lung cancer with 92% sensitivity and 87% specificity.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) has secured approximately
bioAffinity Technologies (NASDAQ: BIAF, BIAFW) announced a publication in PLOS ONE regarding their flow cytometry research on sputum analysis for lung health diagnostics. The study introduces an innovative method for detecting lung cancer and potentially other diseases like COPD and asthma. President and CEO Maria Zannes emphasized the significance of this noninvasive diagnostic approach, stating it may enhance overall diagnostic accuracy, reduce unnecessary procedures, and lower medical costs. bioAffinity's CyPath® Lung test, known for its high sensitivity and specificity, supports early lung cancer detection.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) has successfully completed its initial public offering (IPO), raising approximately $7.8 million through the sale of 1,282,600 units. Each unit consists of one share of common stock and two types of warrants, with exercise prices set at $7.35 and $7.656. The underwriters have an option to purchase up to 192,390 additional shares and/or warrants. The offering, managed by WallachBeth Capital and Craft Capital Management, aims to enhance bioAffinity's efforts in developing noninvasive cancer diagnostics.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced the successful completion of its IPO, raising approximately
bioAffinity Technologies, Inc. (NASDAQ: BIAF) has successfully priced its initial public offering (IPO) of 1,282,600 units at $6.125 per unit, aiming to raise approximately $7.86 million before expenses. Each unit includes one share of common stock and two warrants with exercise prices of $7.35 and $7.656. The IPO proceeds will primarily fund the commercialization of its diagnostic test, CyPath® Lung, which has demonstrated 92% sensitivity and 87% specificity in detecting lung cancer. The shares begin trading on September 1, 2022, under the ticker symbols BIAF and BIAFW.
bioAffinity Technologies, Inc. announced the pricing of its initial public offering (IPO) at $6.125 per unit, raising approximately $7,855,925 before expenses. The offering includes 1,282,600 units, each consisting of one share of common stock and two warrants for future stock purchase. The IPO is set to trade on the Nasdaq under symbols BIAF and BIAFW starting September 1, 2022. Proceeds will support the commercialization of the CyPath® Lung diagnostic test, which demonstrated 92% sensitivity and 87% specificity.